Epsolay® (benzoyl peroxide) cream
Papulopustular Rosacea
ApprovedCommercial (Licensed to Galderma)
Key Facts
Indication
Papulopustular Rosacea
Phase
Approved
Status
Commercial (Licensed to Galderma)
Company
About Sol-Gel Technologies
Sol-Gel Technologies leverages its patented silica-based microencapsulation technology to create novel topical dermatological products with improved efficacy, stability, and patient tolerability. The company transitioned to a commercial-stage entity with the U.S. launch of TWYNEO® in 2022 and is advancing a pipeline targeting acne, rosacea, and other dermatological conditions. Its strategy combines proprietary development with strategic partnerships, such as the license agreement with Galderma for Epsolay® and TWYNEO®, to maximize the reach of its innovative treatments.
View full company profileTherapeutic Areas
Other Papulopustular Rosacea Drugs
| Drug | Company | Phase |
|---|---|---|
| TP-04 (topical lotilaner) | Tarsus Pharmaceuticals | Phase 2a |
| BTX 1702 | Botanix Pharmaceuticals | Pre-clinical / Early Development |